Gene expression profiling has emerged as powerful technique for studying the mechanisms of tumor genesis and development. Seroreactivity profiling of tumor antigens is a more recent technique that further contributes to the understanding of tumors and that offers itself for noninvasive tumor diagnosis. We performed expression profiling of 55 000 transcripts and expressed-sequence-tags for 24 meningiomas and related these data to autoantibody profiles of more than 50 antigens immunogenic in the autologous patients. The expression values of antigens in WHO grade I meningioma were significantly higher if the patients' sera reacted with these antigens as confirmed by a two-tailed Wilcoxon-Mann-Whitney test. Specifically, KIAA1344 that was previously identified as frequent antigen marker in meningioma, showed increased expression if antigens against KIAA1344 were detected in autologous patients. Our study is the first to combine genomewide expression signatures and comprehensive seroreactivity patterns toward a more complete view on tumor immunology, especially concerning the overall role of the level of gene expression on the immunogenicity of meningioma antigens.
Introduction
The goal of our study is to gain further insight into mechanisms underlying the humoral immune response against tumor antigens. Various publications proposed explanations for humoral immune response against tumor antigens, including mutations causing altered proteins, aberrant expression in tissues, overexpression, altered cellular localization and release of intracellular proteins by necrosis. 1 For our proof-of-principal study, we have chosen meningioma that is a genetically rather stable tumor. In addition, many immunogenic antigens that trigger a complex immune response in meningioma patients are already known and can be used for autoantibody profiling. Meningiomas are common tumors of the central nervous system (CNS) arising from the coverings of the brain. The WHO (World Health Organization) classifies meningiomas into three grades. 2 Common type meningiomas (WHO grade I) accounting for about 91% of all meningiomas are slow growing benign tumors. Atypical meningiomas (WHO grade II) account for about 5% of all incidences and are characterized by increased mitotic activity and risk of recurrence. Anaplastic meningiomas (WHO grade III) are malignant tumors that often show invasive growth and a high recurrence rate. Although prognosis is generally good for commontype meningiomas, anaplastic meningiomas show a median survival time of only 2 years after diagnosis.
Only a small number of genes has been associated with meningioma, including NF2 that shows loss of expression in approximately 40% of sporadic meningiomas. [3] [4] [5] A limited number of studies performed cDNA microarray analysis of meningioma. [6] [7] [8] [9] The main focus of those studies was to contribute to the molecular characterization of meningioma and to identify novel genes associated with meningioma development. In addition to these cDNA microarray studies, we reported a variety of antigens that trigger immune response in meningioma patients. 10 Our most recent study ranked these antigens according to their ability to diagnose meningioma. 10 For 24 meningioma patients, we generated the gene expression profiles of tumor samples and the autologous seroreactivity pattern of more than 50 meningiomaassociated antigens. The availability of these comprehensive data sets enabled us for the first time to systematically study the relation between gene expression and immunogenicity of tumor antigens.
Results
Previously, we reported 57 antigens showing reactivity with meningioma sera. 11 For 24 meningioma patients, we measured the autoantibody profile of the 57 meningioma-associated antigens in the patient's blood serum. We excluded 22 antigens that reacted with less than 5 of the 24 leaving a set of 35 antigens. From tumor tissues of the 24 meningioma patients, we generated mRNA expression profiles using the CodeLink Human Whole Genome Bioarray (GE Healthcare, Munich, Germany) targeting more than 55 000 human transcripts and expressed-sequence-tags (ESTs). Combining the information on mRNA expression and autoantibody profiling, we performed two separate analyses: First, we related the overall mRNA expression to autoantibody profiles. Second, we related the expression of the 35 antigens to their seroreactivity.
Overall mRNA expression and autoantibody profiles
We carried out the following computations for each of the 35 antigens: We split the 24 meningioma microarrays in two groups. The first group contains the arrays from patients that show reactivity with the antigen, whereas the second contains the arrays of the patients that do not show reactivity with the antigen. For each of the 55 000 transcripts, we computed the quotients of the median expression values of the two groups and sorted the quotients in decreasing order. Quotients greater than 1.0 indicate that an averaged increased expression of a gene is associated with an antibody response against the considered antigen, whereas quotients smaller than 1.0 mean that a decreased expression of a gene is associated with the detection of the considered antigen. To verify that the observed effects are not due to artifacts in the measured data, we computed 1000 random partitions of the 24 microarrays and computed the sorted lists in the same way as for the real data. For each of the 35 antigens, we tested whether the expression profile contains significantly more up-or downregulated genes than the 1000 random expression profiles. In detail, for each expression profile, we computed the number of genes with quotients greater than a given threshold. Here, we used the thresholds two-and fivefold. The complete analysis is sketched in Figure 1 .
We validated that the 1000 random experiments were normally distributed, calculated the P-values by Z-scores, and adjusted the P-values of the 35 antigens by controlling the false discovery rate (FDR). Thereby, we detected the antigen C6ORF60 to be significant for twofold upregulation (P ¼ 0.00012): C6ORF60 showed 590 transcripts to be upregulated at least twofold. However, only 261 transcripts were upregulated at least twofold in the mean of the 1000 permutation tests (standard deviation of 72). The result of this analysis is shown in Figure 1 (bottom).
For fivefold upregulation, KIAA0999 was significant (P ¼ 0.008): 37 transcripts were above the threshold, 
mRNA expression of immunogenic antigens
Having verified that expression signatures generated from autoantibody profiles show significant deregulation, we addressed the question whether expression values of the antigen encoding genes are significantly higher when the antigens react with patient's serum. To this end, we analyzed the expression levels of each antigen encoding gene i in the following way: we calculated the median expression level of the patients (arrays) where the antigen reacted with the patient's sera and the median expression level of the patients where the antigen did not react with the sera. Finally, we determined the mean value of the 35 quotients as a measure if the expression of reacting antigens is up-or downregulated. The same analysis was carried out for each WHO grade separately. For WHO grade I meningiomas, the mean value of the 35 quotients was 1.35 indicating that the expression values of the 'reacting' patients were increased. To test the significance, we performed permutation tests by randomly shuffling all expression values of each transcript. Here, we obtained a mean value of 1.1. A two-tailed Wilcoxon-MannWhitney test yielded a P-value of 0.018, confirming that expression values of antigens in WHO grade I meningioma are significantly higher if the patientś sera reacted with the antigens (see Figure 2a) .
The analysis described above yielded the highest expression quotients for KIAA1344 (3.1), SASH1 (2.1), ZBTB5 (2.6), RTN4 (3.0) and SWAP70 (5.3). The expression values of KIAA1344 are exemplarily shown in Figure 2b . Although the KIAA1344 expression values for the three serum-negative patients ranged from 0.05 to 0.1, KIAA1344 expression values for the five serumpositive patients ranged from 0.14 to 0.36. Notably, KIAA1344 has been reported as one of the most important meningioma antigen markers with a frequency of 22% in meningioma sera and 0% in nonmeningioma sera and was most suitable to separate meningioma patients from healthy individuals. 10, 12 For grade II/III meningiomas, we did not find elevated mRNA expression for reactive antigens including the aforementioned five antigens. Table 1 summarizes the mean values for each tumor grade, the result of the permutation tests, the quotient of true results over permutation test results and the P-values for each tumor grade.
In addition to the above-described single antigen analysis, we also carried out a 'global' analysis where we assigned the expression values of all antigen coding genes into two groups R and N: for each antigen a and each microarray (patient) m, we add the expression value m(a) of the gene coding antigen a to the group R if antigen a has been detected in the serum of patient m. 
Discussion
This study offers the first attempt to systematically relate expression data to profiles of immunogenic tumor antigens based on a comprehensive data set to gain indepth understanding on the tumor biology, which may lead to improved therapies for human cancers. The expression of 55 000 human transcripts and ESTs was analyzed in 24 meningiomas including eight meningiomas of each WHO grade. We related these data to complex seroreactivity patterns of autologous patients. There are numerous hypotheses why tumor antigens become immunogenic, but most of them await further experimental evidence. Proposed reasons for tumor immunogenicity include overexpression, aberrant expression, mutations, splice variants, posttranslational modification, different cellular localization, release of intracellular proteins, necrosis and apoptosis. 1, 13 Our previous studies with cancer-associated protein database failed to provide evidence that mutations significantly contribute to immunogenicity of tumor antigens. 14 Sequence analysis of several antigens including MGEA6, GLEA2 and EIF4G found in meningioma, glioma and lung cancer, respectively, did not reveal mutations in any of the antigens. 12, 15, 16 Although these three studies were based on tumor-derived libraries, the present study is based on fetal brain libraries. This makes it highly unlikely that mutations are causal for the detected immune response. Equally unlikely are posttranslational modifications as bacterial expression systems such as Escherichia coli are not capable of phosphorylation, acetylation and N-and O-linked glycosylation. Finally, our study did not provide evidence for an influence of the tumor location on the antigen pattern. Our data suggest that the mechanisms underlying the autoantibody response may be even different for various tumors.
The expression values of antigens in WHO grade I meningioma were significantly higher if the patients' sera reacted with these antigens. This was not found for malignant meningioma. Although WHO grade I meningiomas generally show few genetic changes, malignant meningiomas are associated with multiple genetic alterations. These mutations may primarily account for the autoantibody response in WHO grade III meningioma, whereas overexpression may be the main mechanism for WHO grade I meningiomas.
Extended studies will be required to precisely determine the factors underlying autoantibody profiles in tumor patients.
The comparison of comprehensive expression and seroreactivity pattern opens new avenues to systematically examine the relation between gene expression and immunogenicity of tumor antigens. The large Although there is no cellular function known for KIAA1344, RTN4 is a component of CNS myelin and inhibits neurite outgrowth. 17 SWAP70 is believed to be a different type of Rac that transduces signals from tyrosine kinase receptors to Rac in a Ras-independent manner. 18 By testing and validating different statistical hypotheses, we conclude that overexpression has a role as a cause for the humoral response. Notably, we measured significant differentially expressed gene expression profiles for antigens that are highly suited to perform an accurate meningioma diagnosis. Long-term, immunogenic antigens especially when they are overexpressed in meningioma may be appropriate targets for new therapies. However, only very few tumor antigens like NY-ESO-1 have been associated both with a humoral and a cellular immune response. Characterization of the cellular immune response will be a necessary prerequisite for developing the new therapies.
In summary, this study offers the first comprehensive and systematic analysis of expression signatures and seroreactivity signatures. We found significantly higher expression values if the respective antigens were detected with the autologous sera, especially for WHO grade I meningioma. We also found differentially expressed gene expression profiles for those antigens that are best suited for the diagnosis of meningioma.
Materials and methods

Tumor tissues and sera
Tumor tissues and blood samples of patients were obtained from Neurosurgery Department of Saarland University with patient's informed consent. Tissue samples were frozen in liquid nitrogen immediately after surgery and stored at -70 1C. Blood from tumor patients was taken immediately before surgery. All normal sera were randomly selected. Serum was isolated from 10 ml samples using serum gel monovettes and stored at -70 1C.
Tumors were classified and graded using the 2000 WHO scheme. 2 In total, we analyzed eight common type (WHO grade I), eight atypical (WHO grade II) and eight anaplastic meningiomas (WHO grade III).
RNA isolation
RNA was isolated from tumor tissues using Trizol Reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions and subsequently purified using RNeasy Kit (Qiagen, Hilden, Germany). RNA purity and integrity were determined by measuring absorbance at 260 nm in a spectrophotometer and by electrophoresis on denaturing agarose gel.
Microarray analysis
For microarray analysis we used the CodeLink Human Whole Genome Bioarray (GE Healthcare) targeting more than 55 000 human transcripts and ESTs and the CodeLink Expression Assay Reagent Kit according to the manufacturer's instructions. In brief, for first-strand synthesis, 2 mg of tumor total RNA, diluted bacterial mRNA controls and T7 oligo(dT) primer were incubated for 10 min at 70 1C. After addition of first-strand reaction components, synthesis was carried out for 2 h at 42 1C. Second-strand synthesis was performed for 2 h at 16 1C. Double-stranded cDNA was purified using QIAquick PCR Purification Kit (Qiagen). Synthesis of cRNA was carried out by in vitro transcription using biotinylated uridinetriphosphate for 16 h at 37 1C. Labeled cRNA was purified using RNeasy Mini Kit (Qiagen) and subsequently fragmented in fragmentation buffer at 94 1C for 20 min. A total of 10 mg of fragmented cRNA was incubated at 90 1C for 5 min in hybridization buffer, immediately chilled on ice for 5-30 min and then loaded into an array chamber. Slides were hybridized for 18 h at 37 1C and 300 r.p.m. After hybridization slides were washed in 0.75 Â TNT buffer (0.1 M Tris-CI, pH7.6, 0.15 M NaCI, 0.05% Tween20) at 46 1C for 60 min. For detection with streptavidin dye conjugate slides were incubated in Cy5-Streptavidin working solution at ambient temperature for 30 min and washed four times for 5 min with 1 Â TNT. Subsequently, the slides were 
Seroreactivity patterns
Previously, we reported antigen reactivity for 57 immunogenic antigens. Blood of the 24 tumor patients was screened for these 57 antigens. The screening resulted in a binary matrix that contains a '1' at position (i,j), if antigen i reacts with the serum of patient j, otherwise '0'. For more details on the screening, see the reference Comtesse et al.
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Generation of expression profiles
For each antigen A, we generated an expression quotient Q from the autoantibody profile of A. To this end, we computed for each transcript of A on the microarray the median expression value mr of all tumors where a positive immune response against A was detected and the median expression value mn of the tumors where no positive immune response was detected. Thereafter, we computed the expression quotient Q ¼ mr/mn of antigen A. Thus, the value Q reveals if a positive immune response against A in tumors is linked to an up-or downregulated expression of the antigen coding gene.
